ReviewInternational immunopharmacology2012
G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma.
Review in International immunopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Meta-analysis of gene expression profiles in long-term non-progressors infected with HIV-1.BMC medical genomics · 2019Pooled it
- Agonist-specific FPR1 conformational change prevents receptor recycling and promotes targeted protein degradation.Acta pharmaceutica Sinica. B · 2026Article
- The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma.Journal of cellular and molecular medicine · 2026Review
- Mesenchymal stromal cell extracellular vesicles reduceAmerican journal of physiology. Lung cellular and molecular physiology · 2025Article
- Formyl peptide receptor 1 and its antagonist T0080 in atherosclerosis.Cell death and differentiation · 2025Article
- Assessing the potential of bacterial signal peptides for radiopharmaceutical applications.Scientific reports · 2025Article
- Targeting Neutrophil-Mediated Inflammation: Identification of Pyrazolidinone Carboxamide Derivatives as Potent Selective Inhibitors of Formyl Peptide Receptor 1 (FPR1)-Activated Neutrophils.ACS pharmacology & translational science · 2025Article
- Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reducebioRxiv : the preprint server for biology · 2025Article
- Non-alcoholic fatty liver disease and heart failure: A comprehensive bioinformatics and Mendelian randomization analysis.ESC heart failure · 2024Article
- Article
- Integrated analysis of differentially expressed genes and miRNA expression profiles in dilated cardiomyopathy.Heliyon · 2024Article
- Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.European journal of medicinal chemistry · 2023Article
- Integrated bioinformatics analysis of differentially expressed genes in the temporomandibular joint internal derangement.Clinical and experimental dental research · 2023Article
- Characterization of osteosarcoma subtypes mediated by macrophage-related genes and creation and validation of a risk score system to quantitatively assess the prognosis of osteosarcoma and reflect the tumor microenvironment.Annals of translational medicine · 2022Article
- The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression.Biomedicines · 2022Review
- New Insights on Formyl Peptide Receptor Type 2 Involvement in Nociceptive Processes in the Spinal Cord.Life (Basel, Switzerland) · 2022Article
- Review
- Critical role of FPR1 in splenocyte migration into brain to worsen inflammation and ischemic brain injury in mice.Theranostics · 2022Article
- A loss-of-function polymorphism inOncoimmunology · 2022Article
- Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Formylpeptide receptor1 (FPR1) is a G protein-coupled receptor (GPCR) originally identified in phagocytic leucocytes and mediates cell chemotaxis and activation in response to bacterial formylated chemotactic peptides. However, FPR1 also participates in a signal relay which regulates the infiltration of phagocytes, in particular neutrophils, to inflammatory sites in response to tissue-derived chemoattractant ligands. In addition to participating in innate immune responses, recently, FPR1 has been shown to be expressed by highly malignant glioblastoma (GBM) cells. Upon activation by an endogenous agonist Annexin 1 (Anx A1) released by necrotic glioma cells, FPR1 transactivates the receptor for epithelial growth factor (EGFR) and consequently to promote glioma cell chemotaxis, invasion, growth and production of angiogenic factors. The observations demonstrate that FPR1, as a multifunctional GPCR with pattern recognition properties, is not only involved in innate immune responses but also in the progression of GBM. Thus, FPR1 is an immunopharmacologic target for development of novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.